PUBLICATION
There's Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma
- Authors
- Wrighton, P.J., Oderberg, I.M., Goessling, W.
- ID
- ZDB-PUB-190521-9
- Date
- 2019
- Source
- Cellular and molecular gastroenterology and hepatology 8(3): 347-363 (Review)
- Registered Authors
- Goessling, Wolfram
- Keywords
- none
- MeSH Terms
-
- Animals
- Carcinoma, Hepatocellular/genetics
- Carcinoma, Hepatocellular/metabolism
- Carcinoma, Hepatocellular/pathology*
- Disease Models, Animal
- Gene Regulatory Networks*
- Genetic Predisposition to Disease
- Hormones/metabolism
- Humans
- Liver Neoplasms/genetics
- Liver Neoplasms/metabolism
- Liver Neoplasms/pathology*
- Mutation
- Tumor Microenvironment
- Zebrafish
- PubMed
- 31108233 Full text @ Cell Mol Gastroenterol Hepatol
Citation
Wrighton, P.J., Oderberg, I.M., Goessling, W. (2019) There's Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. Cellular and molecular gastroenterology and hepatology. 8(3):347-363.
Abstract
Incidence of and mortality due to liver cancer are increasing. Most patients with hepatocellular carcinoma (HCC) are diagnosed at advanced stages when curative treatments are impossible. Current drug therapy extends mean overall survival by only a short period of time. Genetic mutations associated with HCC vary widely. Therefore, transgenic and mutant animal models are needed to interrogate the molecular effects of specific mutations, classify them as driver or passenger, and develop targeted treatments. Cirrhosis, however, is the premalignant state common to 90% of HCC patients. Yet, currently, no specific therapies are available to halt or reverse the progression of cirrhosis to HCC. Understanding the genetic drivers of HCC as well as the biochemical, mechanical, hormonal, and metabolic changes associated with cirrhosis could lead to novel treatments and cancer prevention strategies. Although additional therapies recently received FDA approval, significant clinical breakthroughs have not emerged since the introduction of the multi-kinase inhibitor sorafenib, necessitating alternate research strategies. Zebrafish (Danio rerio) are effective for disease modeling due to their high degree of gene and organ architecture conservation with humans, ease of transgenesis and mutagenesis, high fecundity, and low housing cost. Here, we review zebrafish models of HCC and identify areas on which to focus future research efforts to maximize the advantages of the zebrafish model system.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping